What is the long-term trend for BioSig Technologies, Inc.'s cash and cash equivalents, end of period?

Over 2 years (2023 to 2025), BioSig Technologies, Inc.'s cash and cash equivalents, end of period has grown at a 934.1% compound annual growth rate (CAGR), from $190K to $20.32M.

BioSig Technologies, Inc. STEX Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Phillips 66PSX

$5.15B+246%

3MMMM

$3.73B-41.1%

eBayEBAY

$4.23B+1.9%

American Financial GroupAFG

$1.35B+6.0%

Erie Indemnity CompanyERIE

$268.62M+3.2%

W.R. BerkleyWRB

$2.28B+32.6%

Other financials

Income statement

See full

Revenue$13.0K+8.3%

Gross profit$12.0K-88.9%

Operating income-$35.7M-1,098%

Net income-$46.7M-1,560%

EPS (diluted)-$0.27-92.9%

Balance sheet

See full

Cash & equivalents$6.9M+84.0%

Total debt$15.0K-94.7%

Total equity$159.0M+6,003%

Total assets$173.3M+3,823%

Cash flow

See full

Operating cash flow-$10.2M-813%

CapEx$4.0K-93.1%

Free cash flow-$2.9M+29.4%

Valuation

See full

Market cap$88.66M-61.8%

P/S2,216.6×-5,967×

Profitability

See full

Gross margin80.1%+25.2pp

Operating margin-32,155%-14,261pp

Net margin-25,825%-11,789pp

FCF margin-97,216.7%-106,293pp

Returns & leverage

See full

Return on equity-627.1%—

Debt / equity0×—

Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioSig Technologies, Inc.'s cash and cash equivalents, end of period?: BioSig Technologies, Inc. (STEX) reported cash and cash equivalents, end of period of $6.86M in Q1 2026.
How has BioSig Technologies, Inc.'s cash and cash equivalents, end of period changed year-over-year?: BioSig Technologies, Inc.'s cash and cash equivalents, end of period increased by 84.0% year-over-year, from $3.73M to $6.86M.
What is the long-term trend for BioSig Technologies, Inc.'s cash and cash equivalents, end of period?: Over 2 years (2023 to 2025), BioSig Technologies, Inc.'s cash and cash equivalents, end of period has grown at a 934.1% compound annual growth rate (CAGR), from $190K to $20.32M.